Inclusion Criteria:  Adult patients (18-80 years old). Female patients. Pathologically proved breast cancer. Breast cancer patients who will receive adjuvant and neoadjuvant weekly paclitaxel for 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance ≤ 2 Adequate bone marrow function. Adequate liver and kidney function.  Exclusion Criteria:  Patients with preexisting clinical neuropathy. Patients with diabetes mellitus. Metastatic breast cancer. Patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics. Patients treated with medications that increase the risk of neuropathy. Hypersensitivity to pentoxifylline or xanthine derivatives. Patients with recent (within 1 month) surgery, myocardial infarction (MI), intracranial or retinal bleeding or active peptic ulcer. Patients at high risk for bleeding or taking medications that increase risk of bleeding.